Page last updated: 2024-12-11

sorbicillin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

sorbicillin: RN given for (E,E)-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5376187
CHEMBL ID4437946
CHEBI ID167836
SCHEMBL ID3122114
MeSH IDM0448973

Synonyms (26)

Synonym
CHEBI:167836
(2e,4e)-1-(2,4-dihydroxy-3,5-dimethylphenyl)hexa-2,4-dien-1-one
sorbicillin
79950-85-9
ACON0_000046
MEGXM0_000242
NCGC00180484-01
ACON1_001459
osrbicilin
BRD-K91836452-001-01-3
2,4-hexadien-1-one, 1-(2,4-dihydroxy-3,5-dimethylphenyl)-, (2e,4e)-
unii-2v94tml24g
3-hydroxy-2,4-dimethyl-6-(1-oxo-hexa-2,4-dienyl)phenol
(2e,4e)-1-(2,4-dihydroxy-3,5-dimethylphenyl)-2,4-hexadien-1-one
2v94tml24g ,
SCHEMBL3122114
RKKPUBAAIGFXOG-YTXTXJHMSA-N
2,4-hexadien-1-one, 1-(2,4-dihydroxy-3,5-dimethylphenyl)-, (e,e)-
(2e,4e)-1-(2,4-dihydroxy-3,5-dimethylphenyl)-2,4-hexadien-1-one #
Q27255645
MS-23330
CHEMBL4437946
HY-146748
CS-0438616
DTXSID601347883
AKOS040734339
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID1624700Anti-allergic activity in rat RBL2H3 cells assessed as reduction in mouse anti-DNP IgE-induced IL-4 level preincubated for 15 mins followed by mouse anti-DNP IgE-stimulation and measured after 3 hrs by ELISA2019Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6
Bisorbicillinol inhibits Lyn tyrosine kinase for allergic response on RBL-2H3 cells.
AID1624703Anti-allergic activity in rat RBL2H3 cells assessed as reduction in calcium ionophore-induced IL-4 level preincubated for 15 mins followed by calcium ionophore stimulation and measured after 3 hrs by ELISA2019Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6
Bisorbicillinol inhibits Lyn tyrosine kinase for allergic response on RBL-2H3 cells.
AID1624710Cytotoxicity in rat RBL2H3 cells assessed as LDH release2019Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6
Bisorbicillinol inhibits Lyn tyrosine kinase for allergic response on RBL-2H3 cells.
AID1624702Anti-allergic activity in rat RBL2H3 cells assessed as reduction in calcium ionophore-induced TNF-alpha level preincubated for 15 mins followed by calcium ionophore stimulation and measured after 3 hrs by ELISA2019Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6
Bisorbicillinol inhibits Lyn tyrosine kinase for allergic response on RBL-2H3 cells.
AID1624699Anti-allergic activity in rat RBL2H3 cells assessed as reduction in mouse anti-DNP IgE-induced TNF-alpha level preincubated for 15 mins followed by mouse anti-DNP IgE-stimulation and measured after 3 hrs by ELISA2019Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6
Bisorbicillinol inhibits Lyn tyrosine kinase for allergic response on RBL-2H3 cells.
AID1888955Toxicity in mouse RAW264.7 cells assessed as reduction in cell vaibility at 10 uM2022Bioorganic & medicinal chemistry, 01-15, Volume: 54Synthesis of sorbicillinoid analogues with anti-inflammation activities.
AID1888954Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production at 10 uM2022Bioorganic & medicinal chemistry, 01-15, Volume: 54Synthesis of sorbicillinoid analogues with anti-inflammation activities.
AID1888958Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced p-NFkappaB protein expression at 10 uM incubated for 24 hrs by Western blot analysis2022Bioorganic & medicinal chemistry, 01-15, Volume: 54Synthesis of sorbicillinoid analogues with anti-inflammation activities.
AID1624698Anti-allergic activity in rat RBL2H3 cells assessed as reduction in mouse anti-DNP IgE-induced beta-hexosaminidase release preincubated for 15 mins followed by mouse anti-DNP IgE-stimulation and measured after 3 hrs by p-nitrophenyl-2-acetamide-2-deoxy-be2019Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6
Bisorbicillinol inhibits Lyn tyrosine kinase for allergic response on RBL-2H3 cells.
AID1624701Anti-allergic activity in rat RBL2H3 cells assessed as reduction in calcium ionophore-induced beta-hexosaminidase release preincubated for 15 mins followed by calcium ionophore-stimulation and measured after 3 hrs by p-nitrophenyl-2-acetamide-2-deoxy-beta2019Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6
Bisorbicillinol inhibits Lyn tyrosine kinase for allergic response on RBL-2H3 cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (5.26)18.7374
1990's0 (0.00)18.2507
2000's4 (21.05)29.6817
2010's12 (63.16)24.3611
2020's2 (10.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.44 (24.57)
Research Supply Index3.04 (2.92)
Research Growth Index4.84 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]